Article Text

PDF
GW24-e1813 The evaluation of the efficacy and safety of percutaneous balloon mitral valvuloplasty with left atrial thrombus in application of the thrombolysis and anticoagulation with low dose of urokinase and low molecular weigh theparin
  1. Wei Xiaojun,
  2. Liao Wei,
  3. Zhong Yi-ming,
  4. Xie Dong-ming
  1. Department of Cardiology, The First Affiliated Hospital of Gannan Medical College, Ganzhou 341000 China

Abstract

Objectives To investigate efficacy and safety of thrombolysis and anticoagulation with low dose of urokinase (UK) and low molecular weight heparin (LWMH) in rheumatic mitral stenosis (MS) patients with left atrial thrombus and percutaneous balloon mitral valvuloplasty (PBMV).

Methods Combination UK was given one time a day in the dose of 20 million U for 5–7 days as well as 4100 U low molecularweight heparin calcium two once a day in rheumatic heart disease patients with thrombosis of the left atrial appendage before surgery. Drugs were suspended 2–3 days before PBMV. haemorrhage, embolism and heart function were observed during and after operation.

Results There were 106 cases with atrial fibrillation and 28 cases with left atrial appendage in 173 patients with PBMV. No serious complications were found during and after operation, such as haemorrhage and embolism. Heart function was significantly improved and 14 patients with atrial fibrillation returned to sinus rhythm after operation.

Conclusions Our data suggest that it is effictive and safe of thrombolysis and anticoagulation treatment with low dose of UK and LWMH in rheumatic mitral stenosis patients with left atrial thrombus before PBMV.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.